News
Public · Published
SYNGENE: Q2 revenue and net profit fell YoY as FX losses surged
Syngene International reported second-quarter revenue of Rs 8,327 million and net profit of Rs 322 million, both below the prior-year figures. First-half net profit was Rs 232 million, reduced by higher foreign-exchange losses and Rs 202 million of termination-benefit exceptional costs.
Published:
Updated:
What happened
Syngene International reported second-quarter revenue of Rs 8,327 million and net profit of Rs 322 million, both below the prior-year figures. First-half net profit was Rs 232 million, reduced by higher foreign-exchange losses and Rs 202 million of termination-benefit exceptional costs.
Confirmed
Global impact / market context
Lower revenue and profit mean the company keeps less cash from each sale, which can limit money available for capital spending, that is investment in facilities and equipment, and may reduce what is left for shareholders. The one-off termination costs are unlikely to repeat, so the underlying profit trend matters more.
Analyst inference
Syngene is a contract research services company, which means it performs research work for other drugmakers. Its results reflect demand for outsourced research and the effect of currency moves on costs and reported profit, giving investors a read on similar service providers.
Analyst inference
What to watch
- Foreign-exchange losses rose and contributed to the profit decline. Watch whether currency moves keep pressuring reported profit, since these losses can reverse quickly and change the profit picture. Confirmed
- Management could explain whether the Rs 202 million termination-benefit charge is fully one-off, which would help investors judge recurring profit. Watch for any guidance on whether similar costs may appear again. Proposed
- Watch whether revenue weakness persists into coming quarters, because falling sales would pressure cash available for capital spending and could affect how investors value Syngene relative to peers. Analyst inference
Evidence
- Original source link unavailable